We would love to hear your thoughts about our site and services, please take our survey here.
Dallo,
Whilst we may rejoice in the recent SP increase from all time lows, the road remains long.
It's been quite a while since the Sp has gone above the benchmark Price on a monthly basis for IMM to receive the full monthly payment from Landstead .
It's also very encouraging that Prof. Muller is still implicated at her ripe young age of 72.
Hopefully we will get some updates on the 'start' of the Lupus trial shortly and that IMM will sign a major commercial deal in the near future.
Supermobileman ,
Once AGAIN, i never said anything about the % of royalties so please don't put words in my moutb !
I did say on numerous occasions today NOT to confuse the Ownership of the IP with the % of royalties due to the CNRS from any revenues !
I also Said, " As far as i know, it's 50/50 OWnership of the patents "
If i am wrong, which IS of course possible , i will of course let thé board know ..
There was nothing misleading in my message of this morning .
The CNRS are still Joint Owners of the IP /patents ...
The fact that they granted exclusive commercial rights to IMM doesn't change that fact..
IMM still needs to collaborate/negociate/ implicate/ the CNRS in any Patent strategy, Is and was the essence of my post this morning
I cannot see what you refer to as misleading or being badly researched or whatever else..
Cauldstream7,
Did you read this part ?
The patents and intellectual property rights to the full Peptide programme are shared jointly by CNRS and Immupharma France SA , a 100% subsidiary of Immupharma plc.
In light of your 'new' found knowledge, do you stand bye Your comment ?
"I don't think you are in a position to lecture people on doing their own research to check on the truth of your unchecked and unresearched statements such as your latest on CNRS and IMM"
Whatever..
Wigwammer,
I am trying to be polite but you are being an as.h.le
When you were complaining this morning that IMM had no or Limited IP protection and therefore no strategy ..
I replied to you that IMM were not alone in deciding on patent protection as they are only Co owners ..
Now , just do your own research before throwing stones !
What a waste of Time and energy
And i stick to that ..supermobileman
50-50 Ownership With the CNRS
Then the CNRS accepted to out license their part to Immupharma for a % of any future revenues.
Anyway, all it takes Anyone IS a few minutes research if they want to DYOR
Wigwammer,
I personaly Take offense to your 'attacks' on my 'person'
Ownership of the patents and licensing royalties are Two different matters...
Just GO and DO YOUR OWN research before throwing stones !!
Machin,
Best of Luck to you here.
I do believe you have found the right entry point but who knows.
As Always said, the COMPANY needs to grow the turn-over , so that shareholders won't need clever Trevor Money ..
Bottom drawer investment for me